Experiment 417260

Details

PropertyValue
Pharmacology
Administration routeIV
OrganismEmpty organism
CitationBISSETT,D: GRAHAM,MA: SETANOIANS,A: CHADWICK,GA: WILSON,P: KOIER,I: HENRAR,R: SCHWARTSMANN,G: CASSIDY,J: KAYE,SB: KERR,DJ:. (1992). PHASE I AND PHARMCOKINETIC STUDY OF RHIZOXIN.. 52(10)
Amount utilized
Compound isolated
Disease24 PATIENTS WITH VARIOUS TUMOR TYPES WERE TREATED IN THIS PHASE 1 STUDY. PATIENTS WERE TREATED WITH DOSES RANGING FROM 0.8 TO 2.6 MG/M2 ONCE EVERY 3 WEEKS UNTIL WITHDRAWAL FROM THE STUDY. THE MOST SEVERE TOXICITIES INCLUDED MUCOSISTS, LEUKOPENIA AND DIARRHEA. OTHER TOXICITIES INCLUDED ALOPECIA, DISCOMFORT AT INJECTION SITE, PERIPHERAL NEUROPATHY, PHLEBITIS, NAUSEA AND VOMITING. PHARMACOKINETIC STUDY SHOWED THE DRUG WAS NOT DETECTABLE AT DOSES OF 0.8 MT/M2 AND 1.6 MG/M2 AND NOT MEASUREABLE 10 MINUTES AFTER INJECTION AT 2.0 MG/M2.
Dose amountVAR
Number1
Qualitative result.
AnimalHUMAN ADULT
Dose expressionDOSE